Author: Alsharidah, Sondas; Ayed, Mariam; Ameen, Reem M.; Alhuraish, Fatma; Rouheldeen, Najat A.; Alshammari, Farah R.; Embaireeg, Alia; Almelahi, Mariam; Adel, Maitham; Dawoud, Mohammed E.; Aljasmi, Mohammad A.; Alshammari, Nashmi; Alsaeedi, Abdullah; Al-Adsani, Wasel; Arian, Hussan; Awad, Husain; Alenezi, Humoud A.; Alzafiri, Azeez; Gouda, Enas F.; Almehanna, Mohammad; Alqahtani, Salem; Alshammari, Abdulrahman; Askar, Medhat Z.
Title: COVID-19 Convalescent Plasma Treatment of Moderate and Severe Cases of SARS-CoV-2 Infection: A Multicenter Interventional Study Cord-id: oghziwn8 Document date: 2020_12_4
ID: oghziwn8
Snippet: Objective To study the effectiveness of CCP therapy for moderate and severe COVID-19 disease patients in Kuwait. Methods This non-randomized prospective cohort study was conducted from May 21, 2020, to June 30, 2020, at four major tertiary hospitals in Kuwait. CCP was administered to 135 patients. The control group comprised 233 patients who received standard treatment. All patients (N = 368, median age 54 [range 15-82] years) had laboratory-confirmed SARS-CoV-2 infection and either moderate or
Document: Objective To study the effectiveness of CCP therapy for moderate and severe COVID-19 disease patients in Kuwait. Methods This non-randomized prospective cohort study was conducted from May 21, 2020, to June 30, 2020, at four major tertiary hospitals in Kuwait. CCP was administered to 135 patients. The control group comprised 233 patients who received standard treatment. All patients (N = 368, median age 54 [range 15-82] years) had laboratory-confirmed SARS-CoV-2 infection and either moderate or severe COVID-19 disease. Results CCP treatment was significantly associated with a higher rate of clinical improvement in patients with moderate or severe disease. Among those with moderate COVID-19 disease, time to clinical improvement was 7 days in the CCP group versus 8 days in the control group (p = 0·006). For severe COVID-19 disease, time to clinical improvement was 7 days in the CCP group versus 15.5 days in the control group (p = 0·003). In the adjusted analysis, the CCP-treated patients with moderate disease had significantly lower 30-day mortality. Compared to the control group, oxygen saturation improved within 3 days of CCP transfusion, and lymphocyte counts improved from day 7 in patients with moderate disease and day 11 in patients with severe disease. Furthermore, C-reactive protein declined throughout the first 14 days after CCP transfusion. None of the CCP patients developed a serious transfusion reaction. Conclusions The data show that administration of CCP is a safe treatment option for patients with COVID-19 disease, with a favorable outcome in the rate and time to clinical improvement.
Search related documents:
Co phrase search for related documents- adjusted model and admission sars infection: 1
- adjusted model and logistic hazard: 1, 2, 3, 4
- adjusted model and logistic hazard regression model: 1
- adjusted model and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- adjusted model and logistic regression analysis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33
- adjusted model and low molecular weight heparin: 1
- adjusted model and lymphocyte count: 1, 2, 3, 4, 5, 6
- admission sars infection and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9
- admission sars infection and logistic regression analysis: 1, 2, 3, 4
- admission sars infection and low molecular weight heparin: 1
- admission sars infection and lymphocyte count: 1, 2
- logistic hazard and lymphocyte count: 1
- logistic regression analysis and low lymphocyte count: 1, 2, 3, 4, 5, 6, 7
- logistic regression analysis and low molecular weight heparin: 1, 2, 3
- logistic regression and low lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- logistic regression and low molecular weight heparin: 1, 2, 3, 4, 5, 6
- logistic regression and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- low lymphocyte count and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- low molecular weight heparin and lymphocyte count: 1, 2, 3, 4
Co phrase search for related documents, hyperlinks ordered by date